Sprintec Kit
Product Images NDC 0555-9016

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Sprintec (NDC 0555-9016). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

Sprintec (norgestimate and ethinyl estradiol) tablets USP 0.250 mg/0.035 mg, 28-day oral tablet kit packaging. The blister card contains 28 circular pills arranged in 4 weekly rows, with the first three rows of pills shaded and the fourth row unshaded. Days of the week are labeled from Sunday to Saturday across the top. Storage instructions indicate to keep at 20° to 25°C (68° to 77°F). The labeler is Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image 2

A forest plot depicting effect estimates (Odds Ratios/Relative Risks) with confidence intervals from multiple studies on contraceptive use. Studies listed by name and year, with graphical points and error bars showing the range of estimates compared to a reference value of 1.0 along the x-axis labeled 'Effect Estimate (OR/RR)'.*

FDA Label Image

Image 3

Chemical structure of Norgestimate, the active ingredient in Sprintec, shown as a detailed molecular diagram with rings and functional groups labeled.*

FDA Label Image

Image 4

Chemical structure of Ethinyl Estradiol, USP, showing its steroid backbone with hydroxyl groups and an ethinyl functional group.*

FDA Label Image

Image 5

An illustration showing different birth control methods categorized by pregnancy rates per 100 women in one year. Methods with fewer pregnancies include implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, and vaginal ring with hormones. Methods with moderate pregnancies include condoms and diaphragm. Higher pregnancy rates are associated with no sex during fertile days, spermicide, and withdrawal, while the highest pregnancy rate is associated with no birth control.*

FDA Label Image

Image 6

Sprintec (norgestimate and ethinyl estradiol) tablets USP 0.250 mg/0.035 mg 28-day tablet pack shown as a weekly pill calendar with circular pill slots arranged in four rows by seven columns representing days Sunday to Saturday, including colored and white pills, labeled by week. The label includes instructions to take all colored pills before white pills and indicates storage temperature (20° to 25°C). Labeled by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image 7

Sprintec 0.250 mg/0.035 mg norgestimate and ethinyl estradiol tablets USP kit packaging label. The label shows a 28-day regimen with 6 blister cards containing 28 tablets each. It includes storage instructions to keep the product at 20° to 25°C and out of reach of children. Labeler information is Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image 8

Sprintec kit containing norgestimate and ethinyl estradiol tablets USP, 0.250 mg/0.035 mg strength. The packaging indicates a 28-day regimen with 6 blister cards of 28 tablets each. Labeler is Teva Pharmaceuticals USA, Inc. The box features the NDC number 0555-9016-58 and includes barcode markings and regulatory information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.